to the FDA Drug Safety and Risk Management Advisory Committee on the
Restrictions on the Use of Lotronex
July 10, 2013
View as PDF.
Public Citizen recommends that restrictions on Lotronex (alosetron) be tightened, rather than loosened, due to its high risk of life-threatening adverse reactions compared with its marginal benefits.